公开(公告)号：US12121588B2

公开(公告)日：2024-10-22

申请号：US16480792

申请日：2018-02-01

申请人： PFIZER INC.

发明人： Kaushik Dutta ,  Jose Manuel Gomes ,  Frank W. Kotch ,  Vimalkumar B. Patel ,  Amarnauth Shastrie Prashad ,  Renee L. Procopio-Melino ,  Xiaotian Zhong

IPC分类号： A61K47/42 ,  A61K47/50 ,  A61K47/64 ,  A61K47/68 ,  C07B31/00 ,  C07B33/00 ,  C07K1/00 ,  C07K16/30 ,  C07K1/107 ,  C07K1/20

CPC分类号： A61K47/6843 ,  A61K47/6855 ,  A61K47/6889 ,  C07K1/00 ,  C07K16/3015 ,  C07K1/1077 ,  C07K1/20 ,  C07K2317/14

摘要： Optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions including the deliberate depletion of cysteine and/or cystine in the cell culture process by way of media components, batch duration, or cell density to achieve efficient production of proteins including antibody-drug-conjugates (ADCs).; conjugating a TNB-capped cysteine-containing protein by reacting it with a reducing agent capable of detaching the TNB-capping moieties from the protein without significantly reducing antibody inter-chain sulfur bonds, and conjugating reduced sulfur bonds on the protein to a payload through a reactive linking moiety.

公开(公告)号：US12016838B2

公开(公告)日：2024-06-25

申请号：US16492142

申请日：2018-03-09

申请人： IZUN PHARMACEUTICALS CORP.

发明人： Shmuel Cohen ,  William Z. Levine ,  Shimon Lecht

IPC分类号： A61K47/50 ,  A61K31/05 ,  A61K31/352 ,  A61K47/12 ,  A61K47/42 ,  A61K47/64

CPC分类号： A61K31/352 ,  A61K31/05 ,  A61K47/12 ,  A61K47/42 ,  A61K47/64 ,  A61K47/643

摘要： A method for producing a fatty acid-cannabinoid-plasma protein (FCP) composition, the method comprising: contacting a plasma protein or a peptide portion thereof with a supplemental fatty acid composition comprising at least one fatty acid; and contacting the plasma protein or portion thereof with a cannabinoid composition comprising at least one cannabinoid, such that a combined composition is prepared, which comprises a FCP complex in which the at least one fatty acid and the at least one cannabinoid is bound to the plasma protein or portion thereof.

公开(公告)号：US20240066144A1

公开(公告)日：2024-02-29

申请号：US18117531

申请日：2023-03-06

申请人： Memorial Sloan Kettering Cancer Center

发明人： Naga Vara Kishore Pillarsetty ,  Steven M. Larson ,  Sang-gyu Lee

IPC分类号： A61K47/69 ,  A61K47/50 ,  A61K47/54 ,  A61K47/60 ,  A61P35/04

CPC分类号： A61K47/6911 ,  A61K47/50 ,  A61K47/547 ,  A61K47/60 ,  A61P35/04 ,  A61K45/06

摘要： Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., livers. Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure of the individual.

公开(公告)号：US11896606B2

公开(公告)日：2024-02-13

申请号：US17095059

申请日：2020-11-11

申请人： HIGHLIGHT THERAPEUTICS, S.L.

发明人： Mercedes Pozuelo Rubio ,  Marisol Quintero Ortiz ,  Ana Villanueva Garcia

IPC分类号： A61K31/713 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  C07K16/28 ,  A61K47/69 ,  A61K47/26 ,  A61K47/50 ,  A61K31/15 ,  A61K31/74

CPC分类号： A61K31/713 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/15 ,  A61K31/74 ,  A61K47/26 ,  A61K47/50 ,  A61K47/6935 ,  C07K16/2818 ,  C07K16/2827

摘要： The present invention relates to compositions comprising particles, each of the respective particles comprising particles formed by polyribonucleotides and polymers. Specifically, the composition comprises a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to methods of manufacturing the compositions, and further to related pharmaceutical compositions useful for the treatment of any cell growth disorder characterized by an abnormal growth of human or animal cells.

公开(公告)号：US20230321224A1

公开(公告)日：2023-10-12

申请号：US18063610

申请日：2022-12-08

申请人： Selecta Biosciences, Inc.

发明人： Christopher Fraser ,  Takashi Kei Kishimoto ,  Roberto A. Maldonado

IPC分类号： A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y5/00 ,  A61K39/36 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K38/18

CPC分类号： A61K39/385 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  A61K39/001 ,  A61K39/0008 ,  A61K9/127 ,  A61K9/5146 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K39/00 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/5115 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K9/5153 ,  A61K38/1816 ,  A61K9/51 ,  G01N2333/70517 ,  G01N2333/70514 ,  G01N2333/7051 ,  A61K2039/5154 ,  A61K2039/577 ,  A61K2039/55511 ,  A61K2039/55555 ,  Y02A50/30 ,  A61K39/35

摘要： Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.

公开(公告)号：US20230116048A1

公开(公告)日：2023-04-13

申请号：US17989526

申请日：2022-11-17

申请人： HIGHLIGHT THERAPEUTICS, S.L.

发明人： Mercedes POZUELO RUBIO ,  Marisol QUINTERO ORTIZ ,  Ana VILLANUEVA GARCIA

IPC分类号： A61K31/713 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  C07K16/28 ,  A61K47/69 ,  A61K47/26 ,  A61K47/50 ,  A61K31/15 ,  A61K31/74

摘要： The present invention relates to compositions comprising polyinosinic (poly(l)) and polycytidylic acid poly(C) molecules, or a salt and/or solvate thereof, comprising double-stranded polyribonucleotides formed by the respective single-stranded poly(l) and poly(C) molecules and methods of makig same. The present invention further relates to compositions wherein the disclosed respective poly(l) and poly(C) single-stranded molecules are annealed to thereby form double-stranded poly(l:C) molecules.

公开(公告)号：US11584787B2

公开(公告)日：2023-02-21

申请号：US16451525

申请日：2019-06-25

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Alan F. List ,  Sheng Wei

IPC分类号： A61K38/17 ,  A61K47/00 ,  A61K47/50 ,  C07K14/705 ,  C07K14/735 ,  C07K19/00 ,  A61K47/69 ,  G01N33/68 ,  A61K38/00

摘要： Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

公开(公告)号：US20220354947A1

公开(公告)日：2022-11-10

申请号：US17552392

申请日：2021-12-16

申请人： Selecta Biosciences, Inc.

发明人： David H. Altreuter ,  Aaron P. Griset ,  Roberto A. Maldonado

IPC分类号： A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y5/00 ,  A61K39/36 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K38/18

摘要： Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

公开(公告)号：US20220267389A1

公开(公告)日：2022-08-25

申请号：US17543213

申请日：2021-12-06

申请人： UNIVERSITÄT BERN

发明人： Achim STOCKER

IPC分类号： C07K14/47 ,  B82Y5/00 ,  B82Y40/00 ,  A61K47/50 ,  A61P25/14 ,  A61P3/02 ,  A61P21/00 ,  A61P19/02 ,  A61P29/00 ,  A61K9/14 ,  A61K9/51 ,  A61K38/17

摘要： The present invention relates to a nanosphere comprising an equal number of a human SEC 14-like protein and a cognate ligand of said SEC 14-like protein as well as to methods of producing the same and uses of said nanospheres.

公开(公告)号：US11326164B2

公开(公告)日：2022-05-10

申请号：US16825131

申请日：2020-03-20

申请人： WJWU & LYNN Institute for Stem Cell Research ,  Mello Biotech Taiwan Co., Ltd.

发明人： Shi-Lung Lin ,  Samantha Chang-Lin ,  Chin-Tsyh Donald Chang

IPC分类号： A61K47/00 ,  A61K47/50 ,  A61K47/51 ,  C12N15/113 ,  A61K39/39 ,  A61K39/29 ,  A61K39/215 ,  A61P35/00 ,  A61K39/21 ,  A61K39/12 ,  A61K39/145

摘要： This invention generally relates to a group of novel chemical compositions and their use for formulating RNA- and/or DNA-based medicine drugs/vaccines into stable compound complexes useful for both in-vitro and in-vivo delivery. Particularly, the present invention teaches the synthesis of a group of novel trimethylglycyl chemicals and their use for formulating cosmetic, therapeutic- and/or pharmaceutical-grade nucleic acid compositions, including but not limited microRNA precursors (pre-miRNA/miRNA), small hairpin RNAs (shRNA), short interfering RNAs (siRNA), ribozymes, antisense oligonucleotides, RNA-DNA hybrids and DNA-based vectors/vaccines, with or without modification, into delivery complexes, which can then be absorbed by cells in vivo, ex vivo and/or in vitro through an active mechanism of endocytosis via acetylcoline receptors for releasing the therapeutic and pharmaceutical effects of the formulated nucleic acid compositions.